The Quantellect read.As of Nov 19, 2026, 7 active firms cover NeoGenomics Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $13.00 to $28.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $19.71 sits 29% above the current $15.29. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.05 next quarter toward $0.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$19.71
+28.9% upside
Average target across 7 active firms as of Nov 19, 2026 vs $15.29 current
Highest Target$28.00
Average Target$19.71
Lowest Target$13.00
Detailed analyst forecasts for NEO
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate NEO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NEO EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.01 – $0.09 · 10 analysts · +440% YoY
Next period, 10 analysts expect NeoGenomics Inc to earn $0.05 a share (range $0.01 – $0.09), versus $0.01 a year earlier. Full-year consensus is $0.20, growing to $0.31 the year after.
REVENUE · NEXT QUARTER
$206.4M
Range $203.1M – $209.0M · 10 analysts · +11% YoY
Revenue is expected to reach $206.4M (range $203.1M – $209.0M), +10.6% year-over-year. Full-year consensus is $808.2M, rising to $886.9M next year.
Top analysts covering NeoGenomics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NEO.
#1
Puneet Souda
Leerink Partners · Rank #30
Buy
$35.00+128.9% to target
Overall win rate
57%
+ Follow
#2
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$11.00-28.1% to target
Overall win rate
40%
+ Follow
#3
Mark Massaro
BTIG · Rank #220
Buy
$28.00+83.1% to target
Overall win rate
44%
+ Follow
#4
Mike Matson
Needham · Rank #285
Buy
$22.00+43.9% to target
Overall win rate
36%
+ Follow
#5
David Westenberg
Piper Sandler · Rank #314
Buy
$13.00-15.0% to target
Overall win rate
35%
+ Follow
NEO stock forecast FAQ
What is NEO's average 12-month price target?+
The 7 active firms with a live target average $19.71 for NeoGenomics Inc over the next 12 months, ranging from a $28.00 high to a $13.00 low, as of Nov 19, 2026.
Is NEO stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NEO?+
The Street-high target is $28.00 (BTIG), and the Street-low is $13.00 (Piper Sandler). The average of all 7 active-firm targets is $19.71.
How many active Wall Street firms cover NEO?+
7 active firms have a recognized rating on NeoGenomics Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NEO?+
Among analysts who currently cover NEO, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Buy with a $35.00 target.
What is NeoGenomics Inc's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.01 – $0.09) across 10 analysts. Full-year EPS is projected at $0.20, rising to $0.31 the following year.
How much revenue is NeoGenomics Inc expected to report next quarter?+
Consensus revenue is $206.4M (range $203.1M – $209.0M). Full-year revenue is projected at $808.2M, growing to $886.9M next year.
Have analysts been upgrading or downgrading NEO lately?+
As of Nov 19, 2026, 7 of 7 active firms rate NEO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NEO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.